Introduction
Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer [HNPCC] ) results from mutations in mismatch repair genes (MLH1, MSH2, MSH6, or PMS2) and is associated with a variety of extra-colonic sites, like endometrium, stomach, ovaries, urinary tract and kidneys, biliary tract, pancreas, small intestine, brain and skin. 1 Endometrial cancer is the most common malignant disorder observed after HNPCC. Case Report 
Discussion
This case demonstrates that Lynch syndrome-related cancer can occur in a patient despite the lack of any family history. This is the first case report of an endometrial cancer patient with a Lynch syndrome germline mutation without family history in Korea.
The risk of developing a second cancer is approximately Approximately 2% to 5% of endometrial cancers may be caused by an inherited susceptibility. 7 In Lynch syndrome carriers, the lifetime risk of endometrial cancer has been estimated to be 42 to 54%, and may equal or exceed the risk of colorectal cancer. 8 Lynch syndrome is caused by a germline mutation in one of the DNA mismatch repair genes (MLH1, MSH2, MSH6, and PMS2), and accounts for the majority of inherited cases. 7 In younger patients, the incidence of endometrial cancer increases to 9% and better survival rates. With the advances in molecular biology now available for the diagnosis of genetic cancers, clinicians can help prevent these cancers by counseling patients and prescribing adequate and appropriate tests.
In known mutation carriers without any colorectal adenomas, screening colonoscopy appears to be the most reasonable choice. 11 However, prophylactic subtotal colectomy remains an option for patients who have significant anxiety about cancer risk or concern about the safety of repeated colonoscopies. Additionally, colectomy can be used if the patient is unable to receive periodic surveillance colonoscopies.
12
More information is required to determine the appropriate genetic tests for counseling and prevention according to the country and ethnicity of the patient.
It is also important to identify patients with Lynch syndrome because families of mutation carriers may benefit from genetic counseling, testing, and intensified cancer surveillance.
In conclusion, gynecological oncologists should provide information of the genetic cancer risk to endometrial cancer patients in an effort to prevent second cancers in patients and family with Lynch syndrome. Patients should undergo the correct genetic tests and should be counseled appropriately, which is important for reducing cancer mortality and costs.
